http://www.engineeringnews.co.za
  SEARCH
Login
R/€ = 13.64Change: 0.00
R/$ = 12.37Change: -0.06
Au 1168.52 $/ozChange: -0.28
Pt 1075.00 $/ozChange: -7.00
 
 
Note: Search is limited to the most recent 250 articles. Set date range to access earlier articles.
Where? With... When?








Start
 
End
 
 
And must exclude these words...
Close Main Search
Close Main Login
My Profile News Alerts Newsletters Logout Close Main Profile
 
Agriculture   Automotive   Chemicals   Competition Policy   Construction   Defence   Economy   Electricity   Energy   Environment   ICT   Metals   Mining   Science and Technology   Services   Trade   Transport & Logistics   Water  
What's On Press Office Tenders Suppliers Directory Research Jobs Announcements Letters Contact Us
 
 
 
RSS Feed
Article   Comments   Other News   Research   Magazine  
 
 
May 25, 2012

Pharmaceuticals giants go head-to-head for intellectual property rights

Back
Expertise|Adcock Ingram|Africa|Defence|Design|Health|Merck & Co|Safety|Testing|Africa|South Africa|Manufacturing|Pharmaceutical Brands|Pharmaceutical Products|Pharmaceuticals|Pharmaceuticals Giant|Pharmaceuticals Heavyweight|Product|Products|Treatment Of Hypertension|Hypertension|Abofele Khoele|Carl Van Rooyen|David Cochrane|Lisinopril|Zemax|Biotechnology
Expertise|Africa|Defence|Design|Health|Safety|Testing|Africa||Manufacturing|Products|||||
expertise|adcock-ingram|africa-company|defence|design|health|merck-co|safety|testing|africa|south-africa|manufacturing|pharmaceutical-brands|pharmaceutical-products|pharmaceuticals|pharmaceuticals-giant|pharmaceuticals-heavyweight|product|products|treatment-of-hypertension|hypertension|abofele-khoele|carl-van-rooyen|david-cochrane|lisinopril|zemax|biotechnology-technology
© Reuse this



The Supreme Court of Appeal (SCA) last month ruled in favour of pharmaceuticals giant Adcock Ingram over a trademark dispute with competitor Cipla Medpro.

The companies locked horns over their registered trademarks for the generic of Lisinopril, which is used to treat mild to moderate hypertension and certain cardiac conditions. Lisinopril was originally patented by international pharmaceuticals heavyweight Merck & Co in 1989.

Last year, Adcock Ingram submitted an application to the Pretoria High Court to have Cipla’s registration for its Zemax trademark revoked, arguing that it was too similar to Adcock Ingram’s Zetomax trademark, which was registered before Zemax.

The High Court dismissed Adcock Ingram’s application, ruling in favour of Cipla. Adcock Ingram then appealed the decision with the SCA, which overturned the High Court ruling last month and ordered that Cipla’s Zemax trademark be removed from the Register of Trademarks.

The SCA also confirmed the right of patients in South Africa to be involved in the process of deciding on their medication, even prescription medication, a decision that countered Cipla’s defence.

Cipla argued that both Zetomax and Zemax can only be obtained with a doctor’s prescription and that, because doctors and pharmacists are trained to know about the products, it is not possible for them to confuse the two competing trademarks.

Cipla’s argument was supported by a 1983 Pretoria High Court decision that found a patient’s prescription to be the sole responsibility of the doctor and not the patient.

The SCA, however, took into account Section 8 of the National Health Act, which gives a patient the right to participate “in any decision affecting his or her personal health and treatment”. The SCA also referred to Section 22(F) of the Medicines and Related Substances Act, which deals with generic substitution.

The SCA agreed with Adcock Ingram that this section of the Medicines and Related Substances Act obliges pharmacists to inform patients of the advantages of generic substitution and so involve patients in the decision-making process. Adcock Ingram’s argument is that the patients contribute to the decision regarding whether trademarks are likely to be confused and their views should, therefore, also be taken into account.

The SCA also remarked that the Pretoria High Court’s 1983 ruling that a patient’s prescription is the doctor’s responsibility is unrealistic in present-day circumstances, where patients play an active role in relation to their health.

“Adcock Ingram is delighted with this ruling,” says medical executive Dr Abofele Khoele, adding that Zetomax will continue to be available as a generic alternative for the treatment of hypertension and certain cardiac conditions.

“The SCA ruling finalised the ongoing debate about whether the views of patients should be taken into account, specifically with regard to the questionable confusion between pharmaceutical brands,” says patent and trademark firm Spoor & Fisher partner Carl van Rooyen, who is also part of Adcock Ingram’s team of attorneys at Spoor & Fisher.

“Pharmaceuticals companies will have to take greater care when choosing names for medicines to ensure they are not confused with other medicines,” he says, adding that this ruling could have far-reaching implications for Cipla, as it will probably be forced to rebrand its Zemax product.

Medical and Pharmaceutical Patents
Trademarks refer specifically to the brand of a particular product and the name that identifies it. Companies who trademark their products are entitled to protect that brand name for the rest of the product’s existence.

Patents, however, which protect new ideas and innovations, are limited to a 20-year period. In the medical and pharmaceuticals world, patents protect products, including the active ingredients in a particular medicine, new pharmaceutical formulations and medical devices.

“The 20-year monopoly provided by a patent incentivises companies to develop new products. Once developed, the product will become available to the generics market.

“However, the development of new pharmaceutical products and medical devices, which involves testing the efficacy and safety of those products and securing regulatory approval to get those products on the market, is very costly,” says Spoor & Fisher patent attorney David Cochrane.

“Most pharmaceuticals companies obtain patents because it’s quite easy to analyse products once they’re on the market,” he says. “So, to protect themselves, most pharmaceuticals companies use patents.”

He adds that the patent document has to provide full details of the product, and that this actually encourages development. “A pharmaceuticals company gets 20 years of protection for bringing in the new product but, in return, [the company has] to share that knowledge to help develop better products.”

However, patents also become contentious issues when it comes to pharmaceutical intellectual property. “It’s about the generic companies wanting to get into the market,” says Cochrane. “If they think the patent is weak or should not have been granted, they can attack that patent and apply for it to be revoked before the 20-year period has ended.”

Alternatively, generic companies wait until the end of the 20-year period and, thereafter, bring the generic of that product onto the market as soon as possible.

Medical devices can also be protected by registered designs, which protect what a product looks like, because each medical device will look different from other devices. A registered design can protect the appearance of a product for up to 15 years.

“Biotechnology is another field where the development of new genes and new technolo- gies is patented,” says Cochrane, adding that attorneys who handle patents in medicine and biology need to have specialised in each specific area to understand it, and know how to protect it by law.

Cochrane mentions that companies like biopharmaceutical discovery company Shimoda Biotech and drug development company iThemba Pharmaceuticals, which are developing new pharmaceutical products, as well as orthopaedic implant specialist Southern Medical, which is developing and manufacturing advanced and high-quality orthopaedic implants, are protecting their research with patents locally and internationally, with a view to commercialising the products internationally.

“We need more South African companies to follow this route,” he says.

Cochrane is a patents attorney with a background in chemistry, whose expertise is handling pharmaceutical patents, formulations and how the active ingredients in medicines are made. “When it comes to biotechnology patents, however, [Spoor & Fisher] has patent attorneys with a biotechnology background who under- stand that technology.”

Similarly, a patent attorney who is also a mechanical engineer, and who under- stands exactly how medical devices work, handles the medical device patenting at the law firm.

Edited by: Chanel de Bruyn
Creamer Media Senior Deputy Editor Online
© Reuse this Comment Guidelines (150 word limit)
 
 
 
 
 
 
 
 
Other Competition Policy News
Economic Development Minister Ebrahim Patel
Some four years after the signing of the Local Procurement Accord, which sketches government’s intention to achieve a 75% localisation spend in the procurement of goods and services, Economic Development Minister Ebrahim Patel has described government’s greatest...
Tanzania's competition commission has initiated a process to cancel approval for East African Breweries' (EABL) 2010 acquisition of a controlling stake in Serengeti Breweries. EABL, owned by Britain's Diageo, sold its 20% stake in Tanzania Breweries five years ago,...
The Competition Commission has reached a settlement agreement with Japanese shipping liner Nippon Yusen Kabushiki Kaisha (NYK) for contravening the Competition Act in the transportation of motor vehicles to and from South Africa by sea. This settlement followed the...
More
 
 
Latest News
An end to wage negotiations within the local government sector could be in sight as a conciliator’s proposal, setting out a number of settlement suggestions to resolve the deadlock, was expected on Monday. The Independent Municipal and Allied Trade Union (Imatu)...
Development financier Eastern Cape Development Corporation (ECDC) executive Noludwe Ncokazi on Friday said the organisation had the “huge responsibility of ensuring business continuity”, following the resignation of ECDC subsidiary Automotive Industry Development...
South Africa’s second-largest oil refinery, Engen Refinery (Enref), is set to undergo a three-day planned maintenance outage from July 9 as part of an ongoing maintenance programme to ensure that the facility, which delivers a significant portion of South Africa’s...
More
 
 
Recent Research Reports
Real Economy Year Book 2015 (PDF Report)
There are very few beacons of hope on South Africa’s economic horizon. Economic growth is weak, unemployment is rising, electricity supply is insufficient to meet demand and/or spur growth, with poor prospects for many of the commodities mined and exported. However,...
Real Economy Insight: Automotive 2015 (PDF Report)
Creamer Media’s Real Economy Year Book comprises separate reports under the banner Real Economy Insight and investigates key developments in the automotive, construction, electricity, road and rail, steel, water, gold, iron-ore and platinum sectors.
Real Economy Insight: Water 2015 (PDF Report)
Creamer Media’s Real Economy Year Book has been divided into individual reports under the banner Real Economy Insight and investigates key developments in the automotive, construction, electricity, road and rail, steel, water, coal, gold, iron-ore and platinum sectors.
Real Economy Insight: Construction 2015 (PDF Report)
Creamer Media’s Real Economy Year Book has been divided into individual reports under the banner Real Economy Insight and investigates key developments in the automotive, construction, electricity, road and rail, steel, water, coal, gold, iron-ore and platinum sectors.
Real Economy Insight: Electricity 2015 (PDF Report)
Creamer Media’s Real Economy Year Book has been divided into individual reports under the banner Real Economy Insight and investigates key developments in the automotive, construction, electricity, road and rail, steel, water, coal, gold, iron-ore and platinum sectors.
Real Economy Insight: Road and Rail 2015 (PDF Report)
Creamer Media’s Real Economy Year Book has been divided into individual reports under the banner Real Economy Insight and investigates key developments in the automotive, construction, electricity, road and rail, steel, water, coal, gold, iron-ore and platinum sectors.
 
 
 
 
 
This Week's Magazine
NHLANHLA NENE The main constraints to economic growth are domestic
Finance Minister Nhlanhla Nene earlier this month stated that, while South Africa’s 2015 economic growth target of 2% was achievable, it was not enough to deliver the tax revenue needed to combat the country’s challenges.
The World Steel Association has published the 2015 edition of the World Steel in Figures report, which shows an increase in steel production as well as provides an overview of steel industry activities from crude steel production to apparent steel use.
The 25-year master plan for Gauteng’s Aerotropolis project will go through a process of approval and adoption during June and July, says Aerotroplis project manager Jack van der Merwe. “We are also in the process of putting together a special purpose vehicle (SPV) to...
SOLAR PANELS The existing buildings in the Coega Industrial Development Zone lent themselves well to rooftop solar panel installations
The Coega Development Corporation (CDC) plans to fit 15 of its buildings, totalling 127 000 m2 of roof space, in the Coega Industrial Development Zone (IDZ), in the Eastern Cape, with solar panels.
The Supreme Court of Appeal’s (SCA’s) November 2014 judgment, ordering steel producer ArcelorMittal South Africa (AMSA) to hand over the 2003 Environmental Master Plan for its Vanderbijlpark steel plant to environmental pressure groups, confirmed the right of civil...
 
 
 
 
 
 
 
 
 
Alert Close
Embed Code Close
content
Research Reports Close
Research Reports are a product of the
Research Channel Africa. Reports can be bought individually or you can gain full access to all reports as part of a Research Channel Africa subscription.
Find Out More Buy Report
 
 
Close
Engineering News
Completely Re-Engineered
Experience it now. Click here
*website to launch in a few weeks
Subscribe Now for $96 Close
Subscribe Now for $96